| 3.56 -0.34 (-8.72%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.72 |
1-year : | 11.56 |
| Resists | First : | 7.47 |
Second : | 9.89 |
| Pivot price | 8.51 |
|||
| Supports | First : | 3.54 |
Second : | 2.95 |
| MAs | MA(5) : | 7.01 |
MA(20) : | 8.68 |
| MA(100) : | 10.11 |
MA(250) : | 11.29 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 15.9 |
D(3) : | 30.5 |
| RSI | RSI(14): 13.7 |
|||
| 52-week | High : | 15.13 | Low : | 3.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EMBC ] has closed below the lower bollinger band by 15.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EMBC ] is to continue within current trading range. It is unclear right now based on current values. 354.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.06 - 4.09 | 4.09 - 4.1 |
| Low: | 3.5 - 3.53 | 3.53 - 3.55 |
| Close: | 3.52 - 3.56 | 3.56 - 3.59 |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Wed, 06 May 2026
Embecta Corp. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Wed, 06 May 2026
Investigation Launched into Embecta Corp. by Johnson Fistel - Intellectia AI
Wed, 06 May 2026
Embecta Corp. (NASDAQ:EMBC) Q2 2026 Earnings Call Transcript - Insider Monkey
Tue, 05 May 2026
Embecta (NASDAQ: EMBC) revenue drops as debt, buyback and Owen Mumford deal reshape 2026 - Stock Titan
Tue, 05 May 2026
Embecta Corp. (NASDAQ:EMBC) Plunges Over 25% on Q2 Fiscal 2026 Miss - ChartMill
Tue, 05 May 2026
Guidance cut, buyback and dividend reduction at Embecta (Nasdaq: EMBC) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 59 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 105.3 (%) |
| Shares Short | 5,800 (K) |
| Shares Short P.Month | 5,620 (K) |
| EPS | 2.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -10.36 |
| Profit Margin | 12.9 % |
| Operating Margin | 29.2 % |
| Return on Assets (ttm) | 18.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -0.4 % |
| Gross Profit (p.s.) | 11.51 |
| Sales Per Share | 18.23 |
| EBITDA (p.s.) | 6.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 214 (M) |
| Levered Free Cash Flow | 189 (M) |
| PE Ratio | 1.5 |
| PEG Ratio | 0 |
| Price to Book value | -0.35 |
| Price to Sales | 0.19 |
| Price to Cash Flow | 0.98 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 4.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|